Vyxeos
Prescribing
Information (PI) PI
  • THE PATIENTS
  • THE FORMULATION
  • THE DATA
  • THE DOSING
  • THE RESOURCES
  • SmPC
  • PI
The patients

Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed, t-AML or AML-MRC1

the patient

Vyxeos Liposomal is indicated for the treatment of adults with newly
diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML
with myelodysplasia-related changes (AML-MRC)1

t-AML and AML-MRC are high-risk subtypes of AML2-5

t-AML

previously untreated AML with a history of prior cytotoxic treatment or radiation therapy4,6

AML-MRC
≥20% blood or marrow blasts4 and any of the following:4,7

AML arising from previous MDS or MPN

De novo AML with MDS-related cytogenetic abnormality

De novo AML with multilineage dysplasia†

Up to 1 in 3‡ newly diagnosed patients may fall into these high-risk categories3,8 and could be eligible for treatment with Vyxeos Liposomal1,9

Vyxeos Liposomal is the first chemotherapy in over 40 years to improve survival vs conventional chemotherapy** in patients with high-risk* AML5
  • † In the absence of mutations of NPM1 or biallelic mutation of CEBPA4
  • ‡ t-AML: ~7% of AML cases3, AML-MRC: ~25% of AML cases8
  • * High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
  • ** Comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given

  • MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm
This website is intended for European Healthcare Professionals only.
REFERENCES
  • Vyxeos Liposomal. European Summary of Product Characteristics.
  • Boddu PC et al. Cancer 2017;123(16):3050-60.
  • Granfeldt Østgård LS et al. J Clin Oncol 2015;33(31):3641-9.
  • Arber DA et al. Blood 2016;127(20):2391-405.
  • Lancet JE et al. J Clin Oncol 2018;36(26):2684-92.
  • National Cancer Institute. Cancer Terms. Available from: www.cancer.gov/publications/dictionaries/cancer-terms/def/t-aml. Accessed May 2020.
  • Weinburg OK et al. Blood 2009;113(9):1906-8.
  • Nagel G et al. Ann Hematol 2017;96(12):1993-2003.
  • Drummond MW. Int J Hematol 2019;8(2):IJH16.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). Adverse events should also be reported to Jazz Pharmaceuticals by email to medinfo-int@jazzpharma.com or phone via +353 1 968 1631 (may include an international call charge).

Job code: INT-VYX-2200141
Date of Preparation: September 2022
Vyxeos
Vyxeos
  • Contact Us
  • Terms of
    Use
  • Privacy
    Statement
  • Cookie
    Policy
  • Prescribing
    Information (PI)
You are being directed to the Jazz corporate website.

Follow link
You are being directed to an external website.
Follow link
This Jazz Pharmaceuticals website has been created for healthcare professionals only.

Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.

I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL

I AM A UK HEALTHCARE PROFESSIONAL

I AM A US HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the UK

https://vyxeos.co.uk
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the US only

https://vyxeospro.com
For European patients and the general public

For more information:

Patient information leaflet
EMA - Information on Vyxeos Liposomal

By clicking here you will be taken to the European Medicines Agency’s external website

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.